indication

Schizophrenic Disorders

Competitive landscape

as of 2026-07-01
Competitive set
6
4 approved · 2 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
34 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 43 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 32 trials
OwnerAstraZeneca
Protection—
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 32 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 42 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Sarcosine
Pipeline · Phase 2
Phase 23 trials
OwnerChina Medical University Hospital
Protection—
drugCompleted
Pomaglumetad
Pipeline · Phase 1
Phase 11 trial
OwnerDenovo Biopharma LLC
Protection—

Market size

prevalence as a range, not a number